Novartis AG (NVS)
NYSE • Healthcare
October 14, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Novartis AG keeps $23 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Oct 27
in 13 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Novartis AG beat expectations on both the top and bottom line in the fiscal second quarter of 2026, reported on July 21, 2026, as revenue fell near 3% to about $14.4 billion, down from about $14.8 billion a year ago, but still topped the about $14.1 billion consensus by +2.4%. Adjusted EPS came in at $2.41, ahead of the $2.17 estimate by +11.1% and down 0.4% from $2.42 a year earlier, while net income fell about 19% to roughly $3.3 billion from about $4.0 billion. Gross profit reached about $10.7 billion, with gross margin near 75% and operating margin about 33%, and the company generated operating cash flow of about $5.9 billion while paying about $2.9 billion in dividends. Consensus for the next period calls for EPS of $2.26 on revenue of $14.57 billion.
Next report — what to expect
Novartis AG is set to report earnings on October 27, 2026. Wall Street’s consensus calls for EPS of $2.24 on revenue of $14.62 billion. For trailing context, revenue declined -2.8% year over year last quarter. Novartis has beaten EPS in 6 of 8 most recent quarters.
About Novartis AG
Novartis AG (NYSE: NVS) is a global pharmaceutical company in healthcare that develops and sells prescription drugs and related medicines, with $54.8 billion of revenue in FY2025. Its business spans innovative branded therapies, generic and biosimilar medicines, and manufacturing capabilities that reach patients, healthcare professionals, and other institutional buyers worldwide.
Today's Snapshot
The day ended with NVS 3.1% higher at 146.88, in line with a firmer sector. Bank of America, an investment bank, kept its CHF 150 price target for Novartis. Earnings are due from NVS on 27 October.
Trading Volume
Below 10d avg (1.7M)
1.6M
vs S&P 500 Today
Strong Outperformance
+4.28%
Updated: October 14, 2026 at 20:18 UTC
NVS Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$143.58 - $148.37Buy
- RSI (14)55.64Neutral
- Stochastic %K (14, 3, 3)65.09Neutral
- MACD Level (12, 26)-0.92Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.